ROSSARI, FEDERICO
 Distribuzione geografica
Continente #
NA - Nord America 1.288
EU - Europa 1.050
AS - Asia 772
SA - Sud America 158
AF - Africa 17
OC - Oceania 2
Totale 3.287
Nazione #
US - Stati Uniti d'America 1.252
RU - Federazione Russa 658
SG - Singapore 330
CN - Cina 198
IT - Italia 168
BR - Brasile 131
HK - Hong Kong 77
VN - Vietnam 70
DE - Germania 49
FR - Francia 41
GB - Regno Unito 34
IN - India 25
NL - Olanda 24
CA - Canada 20
JP - Giappone 19
MX - Messico 15
AR - Argentina 13
BD - Bangladesh 13
PL - Polonia 12
SE - Svezia 12
ES - Italia 9
FI - Finlandia 9
ZA - Sudafrica 7
AT - Austria 6
LT - Lituania 6
CH - Svizzera 5
ID - Indonesia 5
PK - Pakistan 5
SA - Arabia Saudita 5
TR - Turchia 5
CO - Colombia 4
GR - Grecia 4
IQ - Iraq 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
EG - Egitto 3
MA - Marocco 3
SI - Slovenia 3
AU - Australia 2
BE - Belgio 2
IE - Irlanda 2
NP - Nepal 2
PE - Perù 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
UA - Ucraina 2
VE - Venezuela 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
CL - Cile 1
CY - Cipro 1
HN - Honduras 1
IL - Israele 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MD - Moldavia 1
MV - Maldive 1
PH - Filippine 1
PY - Paraguay 1
RS - Serbia 1
UY - Uruguay 1
Totale 3.287
Città #
Dallas 835
Singapore 227
Moscow 120
Ashburn 82
Hong Kong 74
Beijing 52
San Jose 50
Milan 39
Los Angeles 31
New York 31
Ho Chi Minh City 25
Orem 23
Lauterbourg 21
Munich 18
São Paulo 17
Tokyo 17
Rome 16
Santa Clara 16
Hanoi 15
Hefei 14
Shanghai 14
Poplar 13
Council Bluffs 12
Montreal 12
Manchester 11
Frankfurt am Main 10
Warsaw 10
Atlanta 9
Denver 9
Mexico City 9
London 8
Boardman 7
Cesano Boscone 7
Chennai 7
Monza 7
Phoenix 7
Bacoli 6
Berlin 6
Biên Hòa 6
Brooklyn 6
Guangzhou 6
Nuremberg 6
Stockholm 6
Amsterdam 5
Chicago 5
Helsinki 5
Houston 5
Naples 5
Toronto 5
Boston 4
Da Nang 4
Dhaka 4
Johannesburg 4
Mumbai 4
New Delhi 4
Querétaro 4
Riyadh 4
Athens 3
Belo Horizonte 3
Buenos Aires 3
Catania 3
Ljubljana 3
Pelotas 3
Porto Alegre 3
Rio de Janeiro 3
San Francisco 3
Schafisheim 3
Shenzhen 3
São José dos Campos 3
Tianjin 3
Verona 3
Vienna 3
Vilnius 3
Agadir 2
Ankara 2
Bangkok 2
Bari 2
Belford Roxo 2
Bologna 2
Brussels 2
Cape Town 2
Carouge 2
Charlotte 2
Chengdu 2
Cleveland 2
Colombo 2
Dublin 2
Duque de Caxias 2
Falkenstein 2
Forcalquier 2
Formosa 2
Fortaleza 2
Guarulhos 2
Haiphong 2
Helena 2
Honolulu 2
Jinhua 2
Lappeenranta 2
Lucca 2
Maceió 2
Totale 2.081
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 424
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 417
Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models 168
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 115
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 112
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 105
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 102
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 101
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 97
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 93
The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia 92
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 92
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 92
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 91
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 91
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 90
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 84
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 83
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 77
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 73
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 70
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 70
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 69
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 68
A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice 67
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 66
Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-Tnf: Neutrophil-To-lymphocyte ratio and platelet-To-lymphocyte ratio 65
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 63
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 61
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 57
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 57
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 44
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 22
null 7
Gene-based delivery of immune-activating cytokines for cancer treatment 3
Totale 3.388
Categoria #
all - tutte 7.359
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.359


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202316 2 3 0 2 2 1 1 0 2 3 0 0
2023/202442 0 1 5 2 5 4 0 0 0 2 8 15
2024/2025273 18 4 3 13 20 19 30 49 21 15 19 62
2025/20263.056 157 443 589 357 253 119 164 225 636 113 0 0
Totale 3.388